Showing 1 - 8 results of 8 for search 'Yoko K Takada', query time: 0.03s Refine Results
  1. 1
    CD40L Activates Platelet Integrin αIIbβ3 by Binding to the Allosteric Site (Site 2) in a KGD-Independent Manner and HIGM1 Mutations Are Clustered in the Integrin-Binding Sites of CD40L

    CD40L Activates Platelet Integrin αIIbβ3 by Binding to the Allosteric Site (Site 2) in a KGD-Independent Manner and HIGM1 Mutations Are Clustered in the Integrin-Binding Sites of C... by Yoko K. Takada, Michiko Shimoda, Yoshikazu Takada

    Published 2023-07-01
    Get full text
    Article
  2. 2
    Virtual Screening of Protein Data Bank via Docking Simulation Identified the Role of Integrins in Growth Factor Signaling, the Allosteric Activation of Integrins, and P-Selectin as a New Integrin Ligand

    Virtual Screening of Protein Data Bank via Docking Simulation Identified the Role of Integrins in Growth Factor Signaling, the Allosteric Activation of Integrins, and P-Selectin as... by Yoshikazu Takada, Masaaki Fujita, Yoko K. Takada

    Published 2023-09-01
    Get full text
    Article
  3. 3
    The chemokine fractalkine can activate integrins without CX3CR1 through direct binding to a ligand-binding site distinct from the classical RGD-binding site.

    The chemokine fractalkine can activate integrins without CX3CR1 through direct binding to a ligand-binding site distinct from the classical RGD-binding site. by Masaaki Fujita, Yoko K Takada, Yoshikazu Takada

    Published 2014-01-01
    Get full text
    Article
  4. 4
    Pro-Inflammatory Chemokines CCL5, CXCL12, and CX3CL1 Bind to and Activate Platelet Integrin αIIbβ3 in an Allosteric Manner

    Pro-Inflammatory Chemokines CCL5, CXCL12, and CX3CL1 Bind to and Activate Platelet Integrin αIIbβ3 in an Allosteric Manner by Yoko K. Takada, Masaaki Fujita, Yoshikazu Takada

    Published 2022-09-01
    Get full text
    Article
  5. 5
    FGF9, a Potent Mitogen, Is a New Ligand for Integrin αvβ3, and the FGF9 Mutant Defective in Integrin Binding Acts as an Antagonist

    FGF9, a Potent Mitogen, Is a New Ligand for Integrin αvβ3, and the FGF9 Mutant Defective in Integrin Binding Acts as an Antagonist by Chih-Chieh Chang, Yoko K. Takada, Chao-Wen Cheng, Yukina Maekawa, Seiji Mori, Yoshikazu Takada

    Published 2024-02-01
    Get full text
    Article
  6. 6
    A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF antagonist.

    A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF antagonist. by Satoshi Yamaji, Jun Saegusa, Katsuaki Ieguchi, Masaaki Fujita, Seiji Mori, Yoko K Takada, Yoshikazu Takada

    Published 2010-04-01
    Get full text
    Article
  7. 7
    Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling.

    Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling. by Dora Maria Cedano Prieto, Yushen Cheng, Chih-Chieh Chang, Jessica Yu, Yoko K Takada, Yoshikazu Takada

    Published 2017-01-01
    Get full text
    Article
  8. 8
    A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis.

    A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis. by Seiji Mori, Vu Tran, Kyoko Nishikawa, Teruya Kaneda, Yoshinosuke Hamada, Naomasa Kawaguchi, Masaaki Fujita, Jun Saegusa, Yoko K Takada, Nariaki Matsuura, Min Zhao, Yoshikazu Takada

    Published 2013-01-01
    Get full text
    Article

Search Tools: